- Guselkumab (TREMFYA®) is the first IL-23 inhibitor approved for treating adults with moderately to severely active Crohn's disease.
- GRAVITI and GALAXI studies showcased guselkumab's efficacy in inducing and maintaining clinical and endoscopic remission in Crohn's disease patients.
- GRAVITI demonstrated significant clinical remission and endoscopic response compared to placebo.
- GALAXI 2 and 3 studies also yielded positive outcomes, leading to FDA approval.
- Both intravenous and subcutaneous induction options of guselkumab offer added treatment flexibility.
Source: Johnson & Johnson
